00897.HK
Wai Yuen Tong Medicine Holdings Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 0.31
−3.17%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 683.4M | 745.3M | 783.9M | 1.3B |
| Cost of Revenue | 690.4M | 321.5M | 368.8M | 389.1M | 676.9M |
| Gross Profit | 738.4M | 361.9M | 376.5M | 394.8M | 609.5M |
| Operating Expenses | |||||
| R&D Expense | — | 1.9M | 1.1M | 1.8M | 1.9M |
| SG&A Expense | 802.6M | 377.2M | 408.3M | 353.9M | 316.3M |
| General & Admin Expense | 163.3M | — | 109.3M | 108.9M | 106.6M |
| Selling & Marketing Expense | 430.7M | — | 299.0M | 246.1M | 209.7M |
| Other Expenses | — | — | (1.3M) | — | (11.5M) |
| Total Operating Expenses | 802.6M | 379.0M | 408.2M | 355.7M | 558.0M |
| Cost and Expenses | 1.5B | 700.5M | 777.0M | 744.8M | 1.2B |
| Operating Income (EBIT) | (64.3M) | (17.1M) | (31.7M) | 40.9M | 51.6M |
| Non-Operating | |||||
| Interest Income | 85.3M | 39.9M | 45.9M | 45.8M | 44.6M |
| Interest Expense | 45.8M | 17.6M | 28.2M | 40.8M | 29.5M |
| Net Interest Income | 39.6M | 22.3M | 17.7M | 5.0M | 15.1M |
| Other Non-Op Income/Expense | 72.0M | 20.7M | 35.8M | (54.5M) | (60.4M) |
| Non-Operating Income (excl Interest) | (78.9M) | — | (63.9M) | 13.7M | 30.9M |
| EBT (Pre-Tax Income) | 7.2M | 3.6M | 4.1M | (13.6M) | (14.9M) |
| Income Tax Expense | (2.9M) | (445.0K) | (3.0M) | (6.4M) | (15.3M) |
| Bottom Line | |||||
| Net Income | 11.1M | 4.0M | 7.1M | (15.4M) | (20.5M) |
| Earnings from Cont. Ops | 11.2M | 4.1M | 7.1M | (7.3M) | 7.4M |
| Earnings from Discont. Ops | — | — | — | 11.3M | (7.0M) |
| Bottom Line Net Income | 11.1M | 4.0M | 7.1M | (15.4M) | (20.5M) |
| Per Share | |||||
| Basic EPS | HK$0.01 | HK$0.00 | HK$0.01 | (HK$0.01) | (HK$0.02) |
| Diluted EPS | HK$0.01 | HK$0.00 | HK$0.01 | (HK$0.01) | (HK$0.02) |
| Revenue Per Share | HK$1.29 | HK$0.61 | HK$0.66 | HK$0.66 | HK$1.06 |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.2B | 1.2B |
| Diluted Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.2B | 1.2B |
| Profitability Metrics | |||||
| EBITDA | 83.2M | 67.0M | 122.7M | 116.3M | 115.9M |
| D&A | 122.4M | 84.1M | 90.5M | 89.2M | 95.2M |
| EBIT | (39.3M) | (17.1M) | 32.2M | 27.2M | 20.7M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026